药物代谢动力学/药效学指导的CAP优化治疗

Optimization therapy of community- acquired pneumonia supported by pharmacokinetics and pharmacodynamics

社区获得性肺炎（CAP）是急诊科最常见的感染类型，具有高发病率和死亡率，严重威胁着人类的健康。而目前 CAP 临床抗菌药物治疗现状并不乐观，细菌耐药问题日益严重。随着对药物代谢动力学（PK）/药效学（PD）研究的不断深入，依据PK/PD原理指导CAP抗菌药物治疗给药方案的制定和优化，对于提高临床疗效、减少不良反应和防止耐药发生具有重要意义。本文通过对检索相关文献进行综述分析，阐述CAP流行病学现状，对PK/PD指导的优化CAP抗菌治疗进行介绍。

Community-acquired pneumonia（CAP）is one of the most common infectious diseases in the emergency department and a major cause of morbidity and mortality worldwide, which is a serious threat to human health. However, current antibacterial therapy for CAP is unsatisfactory, and the increase in antimicrobial resistance complicates treatment. With the development of pharmacokinetics/pharmacodynamics（PK/PD）, application of PK/PD theory in development and optimization of antibacte-rial dosing regimens is of crucial importance in the enhancement of success therapy, reduction of adverse effects, and minimization of resistance emergence. This paper introduced epidemiology of CAP and opti-mization of antibacterial therapy for CAP under PK/PD theory by reviewing the related articles and com-prehensive analysis.